• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/19/26 4:05:26 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    false 0001734750 0001734750 2026-05-19 2026-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 19, 2026

     

    CORVEX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40254   82-4233771

    (State or other jurisdiction

    of incorporation)

      (Commission File Number)  

    (I.R.S. Employer

    Identification No.)

      

    3401 North Fairfax Drive, Suite 3230,

    Arlington, Virginia

      22226
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (866) GET-GPUS ((866) 438-4787)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   MOVE   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On March 19, 2026, Corvex, Inc., formerly named Movano Inc. (the “Company”) completed its acquisition (the “Merger”) of Corvex Legacy Holdings, Inc., formerly named Corvex, Inc. (“Corvex OpCo”), in accordance with the terms of the Amended and Restated Agreement and Plan of Merger, dated March 19, 2026 (the “Merger Agreement”), by and among the Company, Thor Merger Sub Inc., a wholly-owned subsidiary of the Company (“Merger Sub”), and Corvex OpCo.

     

    Filed herewith as Exhibit 99.1 to this Form 8-K, are (i) the unaudited pro forma condensed combined financial statements of the Company and Corvex OpCo for the three months ended March 31, 2026, as if the Merger had occurred on January 1, 2026 and (ii) the unaudited pro forma condensed combined financial statements of the Company and Corvex OpCo for the year ended December 31, 2025, as if the Merger had occurred on January 1, 2025. The unaudited pro forma condensed combined financial information has been presented consistent with the pro forma financial information previously disclosed in the Company’s Exhibit 99.3 on Form 8-K filed on May 1, 2026. Such presentation has been updated solely to update the classification of certain items in the pro forma condensed combined statements of operations to conform to the Company’s presentation and does not reflect any changes to the underlying transaction accounting adjustments previously reported.

     

    All the pro forma financial statements and other pro forma information included in this Current Report on Form 8-K have been prepared on the basis of certain assumptions and estimates and are subject to other uncertainties and do not purport (i) to reflect what the Company’s actual results of operations or financial condition would have been had the Merger been consummated on the dates assumed for purposes of such pro forma financial statements or (ii) to be indicative of the Company’s financial condition, results of operations or metrics as of or for any future date or period.

     

    Exhibit 99.1 does not modify or update the consolidated financial statements of the Company included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, or of Corvex OpCo included in the Company’s Current Report on Form 8-K/A, filed with the SEC on May 1, 2026, nor does it reflect any subsequent information or events.

     

    The Company is filing as Exhibit 99.2 to this Form 8-K unaudited supplemental non-GAAP financial information.

     

    The information in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01 - Financial Statements and Exhibits.

       

    (d) Exhibits

     

    Exhibit
    Number
      Description
         
    99.1   Unaudited Pro Forma Condensed Combined Financial Information of Corvex, Inc. as of and for the three months ended March 31, 2026 and for the year ended December 31, 2025.
         
    99.2   Unaudited Supplemental Non-GAAP Financial Information
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CORVEX, INC.
         
    Date: May 19, 2026 By: /s/ J Cogan
        J Cogan
        Chief Financial Officer

     

    2

    Get the next $MOVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Co-Chief Executive Officer Crystal John Adler Iii converted options into 4,053,677 shares, increasing direct ownership by 109% to 6,414,723 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:04 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fairbairn Emily converted options into 1,205,282 shares (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:30:26 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    SEC Filings

    View All

    SEC Form S-1 filed by Corvex Inc.

    S-1 - Corvex, Inc. (0001734750) (Filer)

    7/10/26 5:10:53 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Corvex, Inc. (0001734750) (Filer)

    7/7/26 5:10:57 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by Corvex Inc.

    S-8 - Corvex, Inc. (0001734750) (Filer)

    7/1/26 4:58:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Leadership Updates

    Live Leadership Updates

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Financials

    Live finance-specific insights

    View All

    Corvex Reports Q1 2026 Financial Results and Provides Business Update

    Conference Call at 4:30 PM ET / 1:30 PM PTARLINGTON, Va., May 19, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, reported first quarter 2026 results and provided a business update. Reported Q1'26 Highlights:Completed acquisition of Corvex OpCo on March 19, 2026, transitioning the Company's primary business to AI cloud computing and renaming Movano Inc. to Corvex, Inc., effective March 23, 2026.Including 12 days of Corvex OpCo operations in the period, Q1'26 total revenue w

    5/19/26 4:06:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex to Host First Quarter 2026 Earnings Call on Tuesday, May 19, 2026

    Conference Call at 4:30 PM ET/ 1:30 PM PTARLINGTON, Va., May 11, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced that it will hold its first quarter 2026 earnings call on Tuesday, May 19, 2026 at 4:30 pm ET / 1:30 pm PT. Management will host a conference call and live audio webcast to discuss first quarter 2026 results and provide a business update. The live webcast of the earnings conference call can be accessed at the Corvex Investor Relations website at i

    5/11/26 8:30:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CORVEX, INC. ANNOUNCES ADDITIONAL DETAILS OF SPECIAL 35.8% STOCK DIVIDEND FOR SHAREHOLDERS OF RECORD ON MARCH 30, 2026

    ARLINGTON, Va., March 24, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE) ("Corvex" or the "Company") today announced additional details regarding the special 35.8% stock dividend (the "Stock Dividend") previously announced on March 19, 2026.  Each stockholder of record as of the close of business on March 30, 2026 will be entitled to receive a 35.8% stock dividend at no cost and with no action required on the part of the stockholder.For example, a stockholder holding 10,000 shares of Corvex common stock, par value $0.0001 per share (the "Common Stock") as of the close of tradin

    3/24/26 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care